{
    "info": {
        "nct_id": "NCT06710847",
        "official_title": "A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)",
        "inclusion_criteria": "Parts 1, 2, and 3 inclusion criteria:\n\n* Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor\n* Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory\n* Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample\n* Intends to receive GSK4418959 (alone or in combination with PD-1 inhibitor, as determined between Investigator and sponsor) as next line of treatment\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Is expected to have a minimum of 3 months life expectancy\n* Has adequate organ function, as defined in the protocol\n\nParts 1 and 3 inclusion criteria:\n\n• Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options\n\nPart 2 inclusion criteria:\n\n* Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)\n* Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy\n* Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1, as determined by the investigator\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Parts 1, 2, and 3 exclusion criteria:\n\n* Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer therapy-induced AEs\n* Has received prior treatment with a WRN inhibitor\n* Is unable to swallow and retain orally administered study treatment\n* Has symptomatic uncontrolled brain or leptomeningeal metastases\n* Has a known additional malignancy that progressed or required active treatment within the last 2 years because reoccurrence of another malignancy would confound interpretation by RECIST 1.1 criteria. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer that is considered to be low risk for progression by the investigator\n* Has any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs\n* Has severe liver fibrosis\n* Has cirrhosis or current unstable liver or biliary disease\n* Has known hypersensitivity to any of the study interventions or any of their excipients\n* Has known WRN syndrome\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years\n\nPart 3 exclusion criteria:\n\n* Has experienced any of the following with prior immunotherapy: any immune mediated adverse events (imAE) of Grade ≥3, immune-related severe neurologic events of any grade, exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug rash with eosinophilia and systemic signs syndrome [DRESS] syndrome), or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary\n* Has any history of interstitial lung disease or pneumonitis",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Has adequate organ function, as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Has adequate organ function, as defined in the protocol",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory",
            "criterions": [
                {
                    "exact_snippets": "Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening",
                    "criterion": "dMMR/MSI-H status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "known dMMR/MSI-H"
                            ]
                        },
                        {
                            "requirement_type": "determined_by",
                            "expected_value": "certified local laboratory"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of Pre-screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory",
                    "criterion": "MMR/MSI status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "unknown"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of Pre-screening"
                        },
                        {
                            "requirement_type": "to be determined_by",
                            "expected_value": "central reference laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1, as determined by the investigator",
            "criterions": [
                {
                    "exact_snippets": "Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "target lesion"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intends to receive GSK4418959 (alone or in combination with PD-1 inhibitor, as determined between Investigator and sponsor) as next line of treatment",
            "criterions": [
                {
                    "exact_snippets": "Intends to receive GSK4418959 (alone or in combination with PD-1 inhibitor, as determined between Investigator and sponsor) as next line of treatment",
                    "criterion": "planned treatment with GSK4418959",
                    "requirements": [
                        {
                            "requirement_type": "intention to treat",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment regimen",
                            "expected_value": [
                                "GSK4418959 alone",
                                "GSK4418959 in combination with PD-1 inhibitor"
                            ]
                        },
                        {
                            "requirement_type": "treatment line",
                            "expected_value": "next line of treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)",
            "criterions": [
                {
                    "exact_snippets": "histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "Colorectal cancer (CRC)",
                                "Endometrial cancer (EC)"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "advanced",
                                "unresectable",
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor",
            "criterions": [
                {
                    "exact_snippets": "histologically diagnosed",
                    "criterion": "tumor diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": "histological"
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced (unresectable, metastatic or recurrent) solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "stage/type",
                            "expected_value": [
                                "advanced",
                                "unresectable",
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is expected to have a minimum of 3 months life expectancy",
            "criterions": [
                {
                    "exact_snippets": "minimum of 3 months life expectancy",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample",
            "criterions": [
                {
                    "exact_snippets": "Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample",
                    "criterion": "formalin fixed, paraffin embedded (FFPE) sample",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "archival",
                                "fresh"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options",
            "criterions": [
                {
                    "exact_snippets": "histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "histologically diagnosed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has exhausted all standard of care treatment options",
                    "criterion": "standard of care treatment options",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy",
            "criterions": [
                {
                    "exact_snippets": "Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease",
                    "criterion": "lines of systemic anticancer therapy for advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including at least one line of Immune checkpoint inhibitors (ICI) therapy",
                    "criterion": "lines of Immune checkpoint inhibitors (ICI) therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Is unable to swallow and retain orally administered study treatment",
            "criterions": [
                {
                    "exact_snippets": "Is unable to swallow and retain orally administered study treatment",
                    "criterion": "ability to swallow and retain orally administered study treatment",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in the past 2 years",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Parts 1, 2, and 3 exclusion criteria:",
            "criterions": [
                {
                    "exact_snippets": "Parts 1, 2, and 3 exclusion criteria",
                    "criterion": "exclusion criteria for Parts 1, 2, and 3",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has experienced any of the following with prior immunotherapy: any immune mediated adverse events (imAE) of Grade ≥3, immune-related severe neurologic events of any grade, exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug rash with eosinophilia and systemic signs syndrome [DRESS] syndrome), or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary",
            "criterions": [
                {
                    "exact_snippets": "any immune mediated adverse events (imAE) of Grade ≥3",
                    "criterion": "immune mediated adverse events (imAE)",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immune-related severe neurologic events of any grade",
                    "criterion": "immune-related severe neurologic events",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug rash with eosinophilia and systemic signs syndrome [DRESS] syndrome)",
                    "criterion": "exfoliative dermatitis (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or DRESS syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "myocarditis of any grade",
                    "criterion": "myocarditis",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that progressed or required active treatment within the last 2 years because reoccurrence of another malignancy would confound interpretation by RECIST 1.1 criteria. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer that is considered to be low risk for progression by the investigator",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy that progressed or required active treatment within the last 2 years",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression or active treatment within last 2 years",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer that is considered to be low risk for progression by the investigator",
                    "criterion": "type of additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin that has undergone potentially curative therapy",
                                "in situ cancer that is considered to be low risk for progression by the investigator"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has severe liver fibrosis",
            "criterions": [
                {
                    "exact_snippets": "Has severe liver fibrosis",
                    "criterion": "liver fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior treatment with a WRN inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Has received prior treatment with a WRN inhibitor",
                    "criterion": "prior treatment with a WRN inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer therapy-induced AEs",
            "criterions": [
                {
                    "exact_snippets": "Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer therapy-induced AEs",
                    "criterion": "recovery from prior anticancer therapy-induced adverse events (AEs)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "return_to_baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has cirrhosis or current unstable liver or biliary disease",
            "criterions": [
                {
                    "exact_snippets": "Has cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current unstable liver or biliary disease",
                    "criterion": "unstable liver disease",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current unstable liver or biliary disease",
                    "criterion": "unstable biliary disease",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any history of interstitial lung disease or pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "any history of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any history of ... pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs",
            "criterions": [
                {
                    "exact_snippets": "impairment of gastrointestinal function",
                    "criterion": "gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal disease that may significantly alter the absorption of study drugs",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on drug absorption",
                            "expected_value": "may significantly alter the absorption of study drugs"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known hypersensitivity to any of the study interventions or any of their excipients",
            "criterions": [
                {
                    "exact_snippets": "Has known hypersensitivity to any of the study interventions",
                    "criterion": "hypersensitivity to study interventions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known hypersensitivity to ... any of their excipients",
                    "criterion": "hypersensitivity to excipients of study interventions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has symptomatic uncontrolled brain or leptomeningeal metastases",
            "criterions": [
                {
                    "exact_snippets": "Has symptomatic uncontrolled brain ... metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Has symptomatic uncontrolled ... leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known WRN syndrome",
            "criterions": [
                {
                    "exact_snippets": "Has known WRN syndrome",
                    "criterion": "WRN syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Parts 1, 2, and 3 inclusion criteria:",
            "criterions": []
        },
        {
            "line": "Parts 1 and 3 inclusion criteria:",
            "criterions": []
        },
        {
            "line": "Part 2 inclusion criteria:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Part 3 exclusion criteria:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}